Abstracts tagged "Scleroderma"

Abstract Number: 722 • 2014 ACR/ARHP Annual Meeting
Prediction of Improvement in Skin Fibrosis in Diffuse Cutaneous Systemic Sclerosis
Rucsandra Dobrota^1,2, Britta Maurer¹, Nicole Graf³, Carina Mihai², Otylia Kowal-Bielecka⁴, Yannick Allanore⁵ and Oliver Distler on behalf of the EUSTAR investigators and co-authors¹, ¹Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³graf biostatistics, Winterthur, Switzerland, ⁴Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ⁵Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France
Background/Purpose Improvement of skin fibrosis over time is part of the “natural history” of patients with diffuse cutaneous systemic sclerosis (dcSSc). However, in the individual…
Abstract Number: 3002 • 2014 ACR/ARHP Annual Meeting
Anti-Fibrotic Effects of a Newly Discovered HGF Receptor Carboxy-Terminal Fragment in Systemic Sclerosis
Yuichiro Shirai¹, Ilia Atanelishvili², Tanjina Akter¹, Richard Silver³ and Galina Bogatkevich¹, ¹Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC, ³Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose Systemic sclerosis (SSc) is an irreversible fibrotic disorder with interstitial lung disease (ILD) being a major complication and leading cause of mortality. African American…
Abstract Number: 2704 • 2014 ACR/ARHP Annual Meeting
Fatigue in Systemic Sclerosis
Didem Uzunaslan¹, Caner Saygin¹, Tufan Torun², Mehmet Ozdemir² and Gulen Hatemi³, ¹University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: Fatigue is a frequently reported disabling symptom for patients with systemic sclerosis (SSc). It has a major impact on overall quality of life including…
Abstract Number: 1797 • 2014 ACR/ARHP Annual Meeting
One-Year Survival of Adults with Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study
Elana J. Bernstein¹, Eric R. Peterson², Joan M. Bathon² and David J. Lederer², ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Medicine, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Lung transplantation is a potentially life-saving treatment for patients with systemic sclerosis (SSc) who have developed end-stage lung disease due to interstitial lung disease…
Abstract Number: 1721 • 2014 ACR/ARHP Annual Meeting
Investigating the SCF/c-Kit Pathway in Scleroderma Fibrosis
Bahja Ahmed Abdi¹, Oseme Etomi², Xu Shiwen¹, David Abraham³, Christopher Denton³ and Richard J. Stratton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Rheumatology, UCL Medical School, London, United Kingdom, ³Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom
Background/Purpose: Stem cell factor (SCF) is a potential driving factor in the development of systemic sclerosis (SSc) and a possible therapeutic target. SCF is a…
Abstract Number: 874 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial
Dinesh Khanna¹, Christopher P. Denton², Jacob M. van Laar³, Angelika Jahreis⁴, Sabrina Cheng⁴, Helen Spotswood⁵, Jeffrey Siegel⁴ and Daniel E. Furst on behalf of FaSScinate Clinical Trial in Patients With SS⁶, ¹University of Michigan Health System, Ann Arbor, MI, ²University College London Medical School, London, United Kingdom, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴Genentech, South San Francisco, CA, ⁵Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁶University of California, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis.1,2 IL-6 receptor inhibition prevented and…
Abstract Number: 742 • 2014 ACR/ARHP Annual Meeting
Precision of Ultrasound Skin Thickness Measurements: Influence of Examiner and Ultrasound Transducer
Ingeborg A. Sacksen¹, P. Scott Pollock² and Mark H. Wener³, ¹Rheumatology, University of Washington, Seattle, WA, ²Internal Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ³Rheumatology & Lab Med, University of Washington, Seattle, WA
Background/Purpose Ultrasound has been used to measure scleroderma skin thickness, but it has not been established that routine clinical ultrasound equipment is adequate. We compared skin…
Abstract Number: 2919 • 2013 ACR/ARHP Annual Meeting
The Clinical Utility Of Flow-Mediated Dilation In Systemic Sclerosis
Tracy M. Frech¹, Ashley Walker², Zachary Barrett-Okeefe², Russell Richardson², D. Walter Wray² and Anthony Donato², ¹Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ²University of Utah, Salt Lake, UT
Background/Purpose: In systemic sclerosis (SSc, scleroderma) vasculopathy can result in the end-stage manifestation of a digital ulcer (DU). We hypothesized that bedside flow mediated dilatation…
Abstract Number: 682 • 2013 ACR/ARHP Annual Meeting
Effects Of Extracoporeal Shock Wave Therapy To The Digital Ulcers Of Scleroderma:a Pilot Study
Shinichiro Saito¹, Yukiko Kamogawa², Kyohei Nakamura³, Ryu Watanabe³, Tsuyoshi Shirai², Yoko Fujita⁴, Hiroshi Fujii³, Yuko Shirota⁵, Tomonori Ishii³, Hideo Harigae³, Katsuko Kikuchi⁶ and Yasushi Kawaguchi⁷, ¹Department of hematology and rheumatology, Tohoku University, Sendai, Japan, ²Tohoku University, Sendai, Japan, ³Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁴Department of Hematolgy and rheumatolgy, Tohoku University, Sendai, Japan, ⁵Department of Hematology and Rheumatolgy, Tohoku University, Sendai, Japan, ⁶Department of Dermatology, Tohoku University, Sendai, Japan, ⁷Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Vasculopathy, immunological abnormalities and excessive tissue fibrosis are key elements in the pathogenesis of Scleroderma (SSc). In winter, patients often display Raynaud syndrome, which…
Abstract Number: 647 • 2013 ACR/ARHP Annual Meeting
Enhanced Expression of CCR Receptors in Healthy AA and SSc ILD Monocytes
Rebecca Lee¹, Charles Reese², Beth Perry³, Jonathan Heywood², Michael Bonner¹, Richard P. Visconti⁴, Richard M. Silver⁵, Stanley Hoffman³ and Elena Tourkina², ¹Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ²Rheumatology, Medical University of SC, Charleston, SC, ³Rheumatology, Medical University of South Carolina, Charleston, SC, ⁴Cell Biology and Regenerative Medicine, Medical University of South Carolina, Charleston, SC, ⁵Div Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC
Background/Purpose: Scleroderma-associated Interstitial Lung Disease (SSc ILD) is more prevalent and more severe in African Americans (AA) than in Caucasian (C) patients, but little is…
Abstract Number: 662 • 2013 ACR/ARHP Annual Meeting
Oxidative Stress-Dependent Activation Of Collagen Synthesis Is Induced In Human Pulmonary Vascular Smooth Muscle Cells By Scleroderma Sera and Predicts Pulmonary Vascular Disease
Francesco Boin¹, Anna Maria Posadino², Annalisa Cossu², Roberta Giordo², Ami A. Shah¹, Gaia Spinetti³, Gian Luca Erre⁴, Costanza Emanueli⁵, Giuseppe Passiu⁴, Fredrick M. Wigley¹ and Gianfranco Pintus², ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Biomedical Sciences, University of Sassari, Sassari, Italy, ³Istitituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Multi Medica, Milan, Italy, ⁴Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Sassari, Sassari, Italy, ⁵Laboratories of Vascular Pathology and Regeneration, University of Bristol, Bristol, United Kingdom
Background/Purpose: Vascular disease is a dominant component of Systemic Sclerosis (SSc) pathogenesis. Hypoxia and oxidative stress have been linked to endothelial injury, intimal hyperplasia and…
Abstract Number: 786 • 2012 ACR/ARHP Annual Meeting
Crosstalk Between Integrins and TGFβ in the Pathogenesis and Treatment of Multiple Presentations of Scleroderma
Elizabeth E. Gerber¹, Fredrick M. Wigley², Elaine C. Davis³, David L. Huso⁴ and Harry C. Dietz¹, ¹Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Anatomy and Cell Biology, McGill University, Montreal, QC, Canada, ⁴Comparative Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Scleroderma, defined as pathologic fibrosis of the skin, has many clinical presentations. In the most commonly recognized form, systemic sclerosis (SSc), previously healthy individuals…
Abstract Number: 693 • 2012 ACR/ARHP Annual Meeting
A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: Safety and Potential Efficacy
Niamh P. Quillinan¹, Deirdre McIntosh², Syed Haq² and Christopher P. Denton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Daval International Ltd, Eastbourne, East Sussex, United Kingdom
Background/Purpose: We have performed a study to explore safety and tolerability of hyperimmune caprine serum (AIMSPRO®) prepared under GMP conditions in established diffuse cutaneous systemic…
Abstract Number: 697 • 2012 ACR/ARHP Annual Meeting
Demographic, Clinical, Serologic and Socioeconomic Measures Each Predict Mortality in Scleroderma
Allan C. Gelber¹, Rebecca L. Manno², Adrianne Woods¹, Ami A. Shah³, Francesco Boin³, Laura K. Hummers³ and Fredrick M. Wigley³, ¹Medicine/ Rheumatology, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Multivariate Model 1 Adjusted RR 95%CI Multivariate Model 2 Adjusted RR 95%CI Male vs Female 1.4 1.1 – 1.9 Male vs Female 1,4…
Abstract Number: 708 • 2012 ACR/ARHP Annual Meeting
Histological Features of Localized Scleroderma‘en Coup De Sabre‘: A Study of 16 Cases
Takashi Taniguchi, Yoshihide Asano, Zenshiro Tamaki, Kaname Akamata, Naohiko Aozasa, Shinji Noda, Takehiro Takahashi, Yohei Ichimura, Tetsuo Toyama, Miki Sugita, Hayakazu Sumida, Yoshihiro Kuwano, Miki Miyazaki, Koichi Yanaba and Shinichi Sato, Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Scleroderma is a chronic disease of unknown etiology characterized by skin fibrosis and is divided into two clinical entities: localized scleroderma and systemic sclerosis.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].